~500 million people worldwide who are affected by osteoarthritis
There are an estimated 500 million people worldwide who are affected by osteoarthritis, a disease which can cause excruciating pain and make everyday tasks difficult or impossible.
AAV vector to induce expression of clinically validated proteins to target osteoarthritis
Remedium Bio is developing a gene therapy asset which utilizes an FDA-approved AAV vector to induce expression of clinically validated proteins to target mild-moderate osteoarthritis.
USD 20B market
Remedium Bio is aiming to capture the USD 20B mild-moderate osteoarthritis market, which currently has no FDA-approved therapies.
“[The company has a] efficient approach to product development – modular application of proven technologies for the treatment of well characterized pathologies, with a focus on its lead candidate gene therapy, the only single-injection treatment potentially capable of increasing cartilage thickness in Osteoarthritic joints."
Frank Luppino (CEO of Remedium Bio)
Get in touch
Contact us for more information about how we can help you invest in healthcare, biotech, climate tech, or advanced systems.